

Effective November 1, 2018, refer to Palmetto Article A56141



**BlueCross BlueShield
of Alabama**

“Unless otherwise noted, coverage for specific indications is effective the date of the FDA approval of that indication.”

“Please check Approved by Governing Bodies for FDA approval date.”

Name of Blue Advantage Policy: Darzalex® (daratumumab)

Policy #: 670
Category: Pharmacology

Effective Date: November 19, 2018
Latest Review Date: October 2018

Background:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

- 1. Safe and effective;*
- 2. Not experimental or investigational*;*
- 3. Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is: +*
 - Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient’s condition or to improve the function of a malformed body member;*
 - Furnished in a setting appropriate to the patient’s medical needs and condition;*
 - Ordered and furnished by qualified personnel;*
 - One that meets, but does not exceed, the patient’s medical need; and*
 - At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

Description of Procedure or Service:

Darzalex® (daratumumab) is a human anti-CD38 monoclonal antibody (mAb) that targets the CD38 surface protein on myeloma cells. It inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).

Policy:

Effective for dates of service on or after November 1, 2018 refer to Palmetto Article A56141

Effective for dates of service prior to November 1, 2018:

Blue Advantage will treat **Darzalex® (daratumumab)** as a covered benefit for the treatment of individuals with **multiple myeloma**, including plasma-cell leukemia that has not received daratumumab or another anti-CD38 agent for **one** of following indications:

1. When used in **combination** with bortezomib, melphalan, and prednisone for newly diagnosed multiple myeloma who are ineligible for stem cell transplantation; **or**
2. When used as a **single agent** for relapsed or refractory disease following therapy with at least three prior lines of therapy including a proteasome inhibitor (PI) (e.g., bortezomib, carfilzomib, or ixazomib) and an immunomodulatory agent (e.g., thalidomide, lenalidomide, or pomalidomide); **or**
3. When used as **combination therapy** for relapsed or refractory disease following therapy with at least one prior line of therapy including a PI or an immunomodulatory agent when used with one of following:
 - A. Bortezomib and dexamethasone; **or**
 - B. Lenalidomide and dexamethasone.
4. When used in **combination** with pomalidomide and dexamethasone for relapsed or refractory disease following therapy with at least two prior lines of therapy including a PI and lenalidomide

Blue Advantage will treat **Darzalex® (daratumumab)** as a **non-covered benefit** and as **investigational** when the above criteria are not met, and for all other conditions, including but not limited to **any** of the following:

- Presence of human immunodeficiency virus (HIV infection) or hepatitis B virus infection;
- The reason for the treatment is other than for a diagnosis of multiple myeloma, including plasma-cell leukemia.

Effective for dates of service on and after June 30, 2017:

Blue Advantage will treat **Darzalex® (daratumumab)** as a **covered benefit** for the treatment of individuals with **multiple myeloma**, including plasma-cell leukemia that has not received daratumumab or another anti-CD38 agent for **one** of following indications:

1. When used as a **single agent** for relapsed or refractory disease following therapy with at least three prior lines of therapy including a proteasome inhibitor (PI) (for example, bortezomib, carfilzomib, or ixazomib) and an immunomodulatory agent (for example, thalidomide, lenalidomide, or pomalidomide); or
2. When used as **combination therapy** for relapsed or refractory disease following therapy with at least one prior line of therapy including a PI or an immunomodulatory agent when used with one of following:
 - a) Bortezomib and dexamethasone; or
 - b) Lenalidomide and dexamethasone.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

Key Points:

Multiple myeloma is a systemic malignancy of plasma cells that accumulate in the bone marrow, leading to destruction of bone and failure of the bone marrow. Multiple myeloma is highly treatable but rarely curable. However, when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma, it is potentially curable. Multiple myeloma accounts for approximately 10% of all hematologic cancers. The American Cancer Society (ACS) has estimated 30,770 new cases of multiple myeloma will be diagnosed in the United States in 2018, with an estimated 12,770 deaths. The stage of the disease at presentation is a strong determinant of survival, but has little influence on the choice of therapy since almost all individuals (except for those with solitary bone tumors or extramedullary plasmacytomas) have generalized disease. Multiple myeloma affects mostly older individuals around 62 years of age. The age and general health of the individual, prior therapy and the presence of complications of the disease influence treatment selection. The median survival in the pre-chemotherapy era was about 7 months. Multiple myeloma has demonstrated chemosensitivity to initial treatment or treatment for relapsed disease. Improvements in newer treatments have resulted in an increase in 5-year survival which is currently around 50%.

The FDA approval of daratumumab was based on the safety and efficacy demonstrated in two open-label, non-comparative phase II studies. Lokhorst and colleagues reported results on a two-part study, part 1 dose-escalation and part 2 the dose-expansion phase. Part 2 randomly assigned 30 participants to receive daratumumab monotherapy (8 mg per kilogram) and 42 participants to receive daratumumab monotherapy (16 mg per kilogram) administered once weekly for eight doses, twice monthly for eight doses, then monthly for up to 24 months. The study enrolled participants with relapsed multiple myeloma, or disease that was refractory (79%) to two or more different therapies (for example, PI, immunomodulatory agents, chemotherapy, or autologous stem-cell transplantation); participants enrolled had received a median of four prior treatments.

Subjects were at least 18 years of age, with a life expectancy greater than 3 months, ECOG performance status of 0-2, and a measurable level of M protein or free light chains. Pneumonia and thrombocytopenia were identified as the most common adverse events. Serious adverse events occurred in 40% of participants in the 8 mg per kilogram cohort and 33% in the 16 mg per kilogram cohort, with infection-related events the most common among both groups. Lokhorst and colleagues concluded:

The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months.

Lonial and colleagues reported preliminary results of an ongoing phase II open-label, multicenter study of 106 participants (18 years or older) that received daratumumab 16 mg per kilogram in parts 1 and 2; 80% (n=85) of participants had previously undergone autologous stem cell transplantation, 95% of participants (n=101) were refractory to most recent treatment (PI and immunomodulatory agent used), and 97% of participants (n=103) were refractory to last lines of therapy. Final results reported an overall response rate of 29% among participants (n=31) that experienced a complete or partial reduction in tumor burden, which lasted for an average of 7.4 months "(95% CI 5.5 not estimable) and progression-free survival was 3.7 months (95% CI 2.8-4.6). The 12-month overall survival was 64.8% (95% CI 51.2-75.5) and, at a subsequent cutoff, median overall survival was 17.5 months (95% CI 13.7- not estimable)." The most common adverse reactions (any grade) for daratumumab were fatigue (n=42; 40%) and anemia (n=35; 33%). Daratumumab was well tolerated, with no drug-related adverse events that led to discontinuation of treatment. Authors found daratumumab monotherapy an effective option for individuals with relapsed or refractory multiple myeloma for whom available treatments have been exhausted.

The National Comprehensive Cancer Network[®] (NCCN) Drugs and Biologics Compendium[™] and the NCCN CPG for multiple myeloma included recommendations for off-label use of daratumumab for previously treated myeloma for disease relapse or for progressive or refractory disease. The panel offers a category 2A recommendation for use as a single agent in individuals that have received at least three prior therapies, including a PI and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent. The panel included a category 1 recommendation for use of daratumumab when used in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone. The NCCN off-label recommendations are based on interim analysis from a phase II study and two phase III studies that evaluated the use of daratumumab in the treatment of multiple myeloma.

Palumbo and colleagues reported an interim analysis from the CASTOR study, a phase III randomized controlled study that enrolled 498 participants with relapsed or refractory multiple myeloma (RRMM). Subjects were randomly assigned to receive daratumumab in combination with standard of care bortezomib, and dexamethasone (DvD) (n=259) versus the control group

that received bortezomib and dexamethasone (Vd) (n=247), after receiving a partial response from one or more prior therapies (median of two previous lines of therapy). "The primary endpoint was progression-free survival, defined as the time from the date of randomization to the date of disease progression or death, whichever occurred first". Data from the clinical trial showed that daratumumab in combination with standard of care therapy demonstrated a 60.7% reduction in the risk of disease progression or death (PFS) at 12 months compared to 26.9% in the control group population with RRMM. The authors reported additional interim findings:

After a median follow-up period of 7.4 months, the median progression-free survival was not reached in the daratumumab group and was 7.2 months in the control group (hazard ratio for progression or death with daratumumab vs. control, 0.39; 95% confidence interval, 0.28 to 0.53; $P<0.001$). The rate of overall response was higher in the daratumumab group than in the control group (82.9% vs. 63.2%, $P<0.001$), as were the rates of very good partial response or better (59.2% vs. 29.1%, $P<0.001$), as were the rates of very good partial response or better (59.2% vs. 29.1%, $P<0.001$) and complete response or better (19.2% vs. 9.0%, $P=0.001$).

The majority of participants in both groups reported at least one adverse event, with grade 3 or 4 adverse events observed in 76.1% of the daratumumab population and 62.4% of the control population. Commonly reported grade 3 or 4 adverse events among the daratumumab group and the control group were thrombocytopenia (45.3% vs/ 32.9%), anemia (14.4% vs. 16.0%), and neutropenia (12.8% vs. 4.2%). In the daratumumab group, 45.3% of subjects reported infusion-related reactions (majority grade 1 or 2), with 98.2% of infusion-related reactions occurring during the first daratumumab infusion. In conclusion, the authors reported that:

Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than bortezomib and dexamethasone alone.

Dimopoulos and colleagues reported interim results from a randomized, open-label, multicenter phase III trial that enrolled 569 participants with relapsed or refractory multiple myeloma with one or more prior lines of therapy to receive lenalidomide and dexamethasone alone (control group) (n=283) or in combination with daratumumab (n=286). "The primary endpoint was progression-free survival, with progression determined with the use of a validated computer algorithm that combined laboratory results (e.g., M-protein level) and applicable imaging and generated the outcome according to IMWG criteria." Interim analysis was reported at 13.5 months (median follow-up); "169 events of disease progression or death were observed (in 53 of 286 patients [18.5%] in the daratumumab group vs. 116 of 283 [41.0%] in the control group; hazard ratio, 0.34; 95% confidence interval [CI], 0.27 to 0.52; $P<0.001$ by stratified log-rank test)." At 12 months the rate of progression-free survival was "83.2% (95% CI, 78.3 to 87.2) in the daratumumab group, as compared with 60.1% (95% CI, 54.0 to 65.7) in the control group". The overall response rate observed in the daratumumab group was 92.9% compared to 76.4% among the control group; the complete response was also higher in the daratumumab group, 43.1% versus a rate of 19.2% in the control group. Grade 3 or 4 adverse events commonly reported among the daratumumab group and the control group included neutropenia (51.9% vs 37.0%), thrombocytopenia (12.7% vs 13.5%) and anemia (12.4% vs. 19.6%). Infusion-related

reactions occurred in 47.7% of participants in the daratumumab group; the majority reported as grade 1 or 2 adverse events. The authors concluded that "the addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma."

The FDA approval for expanded use of daratumumab in combination with pomalidomide and dexamethasone was based on unpublished data from a cohort of a phase 1 (MMY1001, EQUULEUS) study that investigated the safety and tolerability of daratumumab in combination with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma. The phase 1, open-label study included 103 participants with multiple myeloma who received prior treatment with PI and an immunomodulatory agent. The overall response rate observed in the study was 59% (95% CI, 49.1%-68.8%) and partial response achieved in 28% of participants. The median duration of response reported was 13.6 months. Among participants that received treatment, grade 3 or 4 serious adverse events were reported in 5% of participants, including pneumonia, neutropenia, thrombocytopenia and anemia.

Mateos and colleagues (2017) reported interim analysis from a multicenter, randomized, open-label, phase 3 trial (NCT02195479) that enrolled participants with newly diagnosed multiple myeloma, ineligible for high-dose chemotherapy with stem-cell transplantation due to age greater than or equal to 65 years, or in participants less than 65 years of age with presence of comorbid conditions likely to have a negative impact on tolerability of high-dose chemotherapy with stem cell transplantation. A total of 700 participants received the assigned intervention, 346 participants in the daratumumab group (daratumumab in combination with bortezomib, melphalan, and prednisone) and 354 participants in the control group (bortezomib, melphalan, and prednisone alone). The primary endpoint was PFS, "defined as the time from randomization to either disease progression or death." The authors reported interim findings:

The 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; $P<0.001$). The overall response rate was 90.9% in the daratumumab group, compared with 73.9% in the control group ($P<0.001$), and the rate of complete response or better (including stringent complete response) was 42.6%, versus 24.4% ($P<0.001$).

The most common grade 3 or 4 adverse events reported among the daratumumab group and the control group included neutropenia (39.9% vs 38.7%), thrombocytopenia (34.4% vs 37.6%) and anemia (15.9% vs. 19.8%). Infusion-related reactions occurred in 47.7% of participants in the daratumumab group; the majority reported as grade 1 or 2 adverse events. The authors concluded that daratumumab combined with bortezomib, melphalan, and prednisone in individuals newly diagnosed with multiple myeloma who were ineligible for stem cell transplantation resulted in a lower risk of disease progression or death than treatment with bortezomib, melphalan and prednisone.

Daratumumab is also currently being studied in clinical trials for other uses including, but not limited to the treatment of acute myeloid leukemia (AML), relapsed/refractory mantle cell

lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. However, there is insufficient published evidence to support the use of daratumumab for such conditions.

Key Words:

Darzalex, daratumumab, multiple myeloma

Approved by Governing Bodies:

On November 16, 2015 daratumumab was the first human mAb to achieve accelerated approval and breakthrough therapy status by the U.S. Food and Drug Administration (FDA), because it provided an option for individuals with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent. The FDA approved daratumumab injection for intravenous infusion to be used as a single agent for the treatment of relapsed or refractory disease

On November 21, 2016, daratumumab was FDA approved for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Benefit Application:

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

Current Coding:

CPT Codes:

J9145 Injection, daratumumab, 10mg

References:

1. American Cancer Society. Cancer facts & figures 2016. Atlanta: American Cancer Society; 2016.
2. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
3. DARZALEX [Product Information], Horsham, PA. Janssen Biotech, Inc; November 16, 2015. Available at: www.darzalex.com/shared/product/darzalex/darzalex-prescribing-information.pdf.
4. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011; 186(3):1840-1848.
5. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:1319-1331.

6. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. *N Engl J Med*. 2015; 373(13):1207-1219.
7. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomized, phase 2 trial. *Lancet*. 2016; 387(10027):b1551-1560.
8. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med*. 2017. DOI: 10.1056/NEJMoal714678. [Epub ahead of print]
9. National Cancer Institute. Surveillance, Epidemiology, and Ends Results (SEER) Program. Cancer Stat Facts: Myeloma. Available at: www.seer.cancer.gov/statfacts/html/mulmy.html
10. National Comprehensive Cancer Network®. NCCN Drugs & Biologic Compendium™ (electronic version). For additional information visit the NCCN website: www.nccn.org.
11. NCCN Clinical Practice Guidelines in Oncology®. © 2018 National Comprehensive Cancer Network, Inc. Multiple myeloma (V.1.2019). Available at: www.nccn.org/index.asp.
12. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016; 375:754-766.

Policy History:

Adopted for Blue Advantage, May 2017

Available for comment May 15, 2017 through June 29, 2017

Medical Policy Group, October 2018 (2): Updates to Key Points, Approved by Governing Bodies, and References; Policy section updated with criteria for combination therapy for newly diagnosed multiple myeloma and relapsed/refractory disease after at least two prior lines of therapy, also added investigational statement for HIV or hepatitis B vaccine.

Available for comment October 5, 2018 through November 19, 2018

Medical Policy Group, November 2018

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.